Psoriatic arthritis registries

Piercarlo Sarzi-Puttini; Valentina Varisco; Maria Chiara Ditto; Maurizio Benucci; Fabiola Atzeni

doi:10.3899/jrheum.150631

Psoriatic arthritis registries

Piercarlo Sarzi-Puttini, Valentina Varisco, Maria Chiara Ditto, Maurizio Benucci, Fabiola Atzeni

IRCCS Istituto Ortopedico Galeazzi

Research output: Contribution to journal › Article › peer-review

Abstract

The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data. The Journal of Rheumatology

Original language	English
Pages (from-to)	30-32
Number of pages	3
Journal	Journal of Rheumatology
Volume	93
DOIs	https://doi.org/10.3899/jrheum.150631
Publication status	Published - Nov 1 2015

Keywords

Adverse events
Biological drugs
Psoriatic arthritis
Registries

ASJC Scopus subject areas

Rheumatology
Immunology
Immunology and Allergy

Access to Document

10.3899/jrheum.150631

Cite this

@article{a4917c86a7264b258b449f280a62ff41,

title = "Psoriatic arthritis registries",

abstract = "The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data. The Journal of Rheumatology",

keywords = "Adverse events, Biological drugs, Psoriatic arthritis, Registries",

author = "Piercarlo Sarzi-Puttini and Valentina Varisco and Ditto, {Maria Chiara} and Maurizio Benucci and Fabiola Atzeni",

year = "2015",

month = nov,

day = "1",

doi = "10.3899/jrheum.150631",

language = "English",

volume = "93",

pages = "30--32",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Psoriatic arthritis registries

AU - Sarzi-Puttini, Piercarlo

AU - Varisco, Valentina

AU - Ditto, Maria Chiara

AU - Benucci, Maurizio

AU - Atzeni, Fabiola

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data. The Journal of Rheumatology

AB - The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data. The Journal of Rheumatology

KW - Adverse events

KW - Biological drugs

KW - Psoriatic arthritis

KW - Registries

UR - http://www.scopus.com/inward/record.url?scp=84962859545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962859545&partnerID=8YFLogxK

U2 - 10.3899/jrheum.150631

DO - 10.3899/jrheum.150631

M3 - Article

C2 - 26523052

AN - SCOPUS:84962859545

VL - 93

SP - 30

EP - 32

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

ER -

Psoriatic arthritis registries

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this